Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

NCT03047928 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
48
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Inge Marie Svane